ERBB2 and breast cancer: According to Dr. Kalinsky and colleagues, the updated and peer-reviewed findings from the RxPonder trial suggest that postmenopausal women HR-positive, HER2-negative early breast cancer with 1-3 positive lymph nodes and an Oncotype DX recurrence score of 0-25 can safely forgo adjuvant chemotherapy without compromising long-term IDFS and DRFS.